Treatment of diabetes
US9988447B2 · kind B2 · utility
1Cited by
0References
8Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 30, 2016 |
| Grant date | Jun 5, 2018 |
| Priority date | — |
| Expiry date | Nov 30, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/545
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Glycated hemoglobin (HbA1c) levels and other characteristics of diabetes are reduced by administering to a human subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.